BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 10, 2026
Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Vertex Starts 24-Week Telaprevir Phase III Study in HCV Patients

Jan. 24, 2008
By Jennifer Boggs

Vertex Starts 24-Week Telaprevir Phase III Study in HCV Patients

Jan. 24, 2008
By Jennifer Boggs

Teva Buying HGS Spinout CoGenesys for $400M Cash

Jan. 23, 2008
By Jennifer Boggs
Privately held CoGenesys Inc., a 2006 spinout of Human Genome Sciences Inc., is being acquired by potential collaborator Teva Pharmaceutical Industries Ltd. in a $400 million cash deal. (BioWorld Today)
Read More

Teva Buying HGS Spinout CoGenesys for $400M Cash

Jan. 23, 2008
By Jennifer Boggs
Privately held CoGenesys Inc., a 2006 spinout of Human Genome Sciences Inc., is being acquired by potential collaborator Teva Pharmaceutical Industries Ltd. in a $400 million cash deal. (BioWorld Today)
Read More

Seattle Genetics Boosts Antibody Work with $90M Public Offering

Jan. 22, 2008
By Jennifer Boggs
Coming off a year in which it advanced its multi-drug clinical-stage pipeline and scored a major deal with Genentech Inc., Bothell, Wash.-based Seattle Genetics Inc. has given no indication of slowing down, as it starts 2008 with a $90 million public offering. (BioWorld Today)
Read More

Seattle Genetics Boosts Antibody Work with $90M Public Offering

Jan. 22, 2008
By Jennifer Boggs
Coming off a year in which it advanced its multi-drug clinical-stage pipeline and scored a major deal with Genentech Inc., Bothell, Wash.-based Seattle Genetics Inc. has given no indication of slowing down, as it starts 2008 with a $90 million public offering. (BioWorld Today)
Read More

MAP, FDA Agree on SPA for Inhaled Migraine Drug

Jan. 17, 2008
By Jennifer Boggs

MAP, FDA Agree on SPA for Inhaled Migraine Drug

Jan. 17, 2008
By Jennifer Boggs

XenoPort's RLS Drug Reduces Relapse Rate In Phase III Trial

Jan. 16, 2008
By Jennifer Boggs

XenoPort's RLS Drug Reduces Relapse Rate In Phase III Trial

Jan. 16, 2008
By Jennifer Boggs
Previous 1 2 … 188 189 190 191 192 193 194 195 196 … 340 341 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 9, 2026
  • 3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

    Skape Bio unlocks GPCR targets with de novo-designed miniproteins

    BioWorld
    Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
  • Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

    BioWorld Science
    Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
  • Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors

    BioWorld Science
    Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing